Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience. Issue 1 (2nd January 2017)

• Record Type: Journal Article
• Authors: Heiblig, Maël; Le Jeune, Caroline; Elhamri, Mohamed; Balsat, Marie; Tigaud, Isabelle; Plesa, Adriana; Barraco, Fiorenza; Labussière, Hélène; Ducastelle, Sophie; Nicolini, Franck; Wattel, Eric; Salles, Gilles; Thomas, Xavier
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 1(2017)
• Page Start: 110
• Page End: 117
• Publication Date: 2017-01-02
• Subjects: Acute myeloid leukemia -- elderly -- prognosis -- treatment; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1180688
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The treatment of very elderly patients (≥70 years) with acute myeloid leukemia remains controversial. We present here 302 patients seen over a 14-year period in order to understand the real-world treatment patterns and outcomes in this patient population. Less than 25% of patients achieved a complete remission. The median overall survival was 12.4, 11.5 and 2.6 months, with a 3-year rates of 27%, 17% and 6%, for non-acute promyelocytic leukemia patients receiving intensive chemotherapy, lower-intensity therapy or best supportive care (BSC), respectively. In all ages, results were not significantly different among patients receiving low-intensity therapy and intensive chemotherapy, but significantly worse in those treated with BSC only. Similarly, intensive chemotherapy and low-intensity therapy gave better survival rates than BSC in patients with favorable- or intermediate-risk cytogenetics and in those with unfavorable cytogenetics ( p < 0.0001 and p = 0.04, respectively).